Burning Rock Biotech (BNR) EBITDA (2019 - 2026)

Burning Rock Biotech's EBITDA history runs 8 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, EBITDA fell 30.48% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$8.3 million (up 75.6% YoY), while the FY2025 annual figure was -$7.7 million, up 84.21% from the prior year.
• EBITDA for Q1 2026 stood at -$2.7 million, down from -$1.7 million in the prior quarter.
• The five-year high for EBITDA was -$1.6 million in Q2 2025, with the low at -$41.5 million in Q1 2022.
• The 5-year median for EBITDA is -$17.4 million (2024), against an average of -$17.6 million.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 58.08% in 2022, then surged 89.51% in 2025.
• Burning Rock Biotech's EBITDA stood at -$31.5 million in 2022, then gained by 25.69% to -$23.4 million in 2023, then surged by 52.09% to -$11.2 million in 2024, then surged by 84.67% to -$1.7 million in 2025, then tumbled by 58.69% to -$2.7 million in 2026.
• Business Quant data shows BNR's EBITDA at -$2.7 million in Q1 2026, -$1.7 million in Q4 2025, and -$2.3 million in Q3 2025.